US ban on Ranbaxy drugs & India pharma
D G Shah Secretary General IPA* A sense of doom is not at all warranted THE recent FDA action is a warning for several other companies that are already in the US market or intend to enter it in the near future. Just as they had learnt to emulate the success of the pioneering efforts of Ranbaxy, they will learn the hard lessons from the recent experience of Ranbaxy.
Related Content
- In new pharma pricing policy, hope beyond bitter pill
- Cabinet okays pharma pricing policy
- US to charge fee on generic drug sale application
- Shifting Focus: Pharma MNCs Now Look to Tie-Ups with Indian Firms
- FDI Curbs in Pharma Could Deter MNCs: Pfizer India MD
- Delhi HC rejects BMS plea to ban Ranbaxy generic